Exposure-response analyses for optimal therapeutic dose selection of ABBV-383 in patients with relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Polepally, Akshanth
Badillo, Jesus D.
de Almeida, Carla Biesdorf
Voorhees, Peter M.
D'Souza, Anita
Kumar, Shaji
Bueno, Orlando Felix
Rosenberg, Tanya
Pothacamury, Rajvineeth Kumar
Talati, Chetasi
Menon, Rajeev
Mensing, Sven
Engelhardt, Benjamin
机构：
[1] AbbVie Inc, Ludwigshafen, Germany
[2] Wake Forest Univ, Levine Canc Inst, Plasma Cell Disorders Sect,Atrium Hlth, Dept Hematol Oncol & Blood Disorders,Sch Med, Charlotte, NC USA
[3] Froedtert & Med Coll Wisconsin Canc Ctr, Div Hematol Oncol, Dept Med, Milwaukee, WI USA
[4] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7541
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma
    Miao, Xin
    Wu, Liviawati S.
    Lin, Shun Xin Wang
    Xu, Yan
    Chen, Yang
    Iwaki, Yuki
    Kobos, Rachel
    Stephenson, Tara
    Kemmerer, Kristy
    Uhlar, Clarissa M.
    Banerjee, Arnob
    Goldberg, Jenna D.
    Trancucci, Danielle
    Verona, Raluca
    Pei, Lixia
    Su, Yaming
    Ouellet, Daniele
    Garfall, Alfred L.
    Krishnan, Amrita Y.
    Usmani, Saad
    Girgis, Suzette
    Zhou, Honghui
    BLOOD, 2022, 140 : 4382 - 4383
  • [22] Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
    Miao, Xin
    Wu, Liviawati S.
    Lin, Shun Xin Wang
    Xu, Yan
    Chen, Yang
    Iwaki, Yuki
    Kobos, Rachel
    Stephenson, Tara
    Kemmerer, Kristy
    Uhlar, Clarissa M.
    Banerjee, Arnob
    Goldberg, Jenna D.
    Trancucci, Danielle
    Apte, Amit
    Verona, Raluca
    Pei, Lixia
    Desai, Rachit
    Hickey, Kathleen
    Su, Yaming
    Ouellet, Daniele
    Samtani, Mahesh N.
    Guo, Yue
    Garfall, Alfred L.
    Krishnan, Amrita
    Usmani, Saad Z.
    Zhou, Honghui
    Girgis, Suzette
    TARGETED ONCOLOGY, 2023, 18 (05) : 667 - 684
  • [23] CHARACTERIZING EXPOSURE-RESPONSE RELATIONSHIPS OF IDECABTAGENE VICLEUCEL IN PATIENTS WITH TRIPLE-CLASS-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Zhou, J.
    Burnett, J.
    Zheng, X.
    Chen, Y.
    Caia, A.
    Cook, M.
    Kondic, A.
    Lamba, M.
    Wu, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S82 - S82
  • [24] Mezagitamab Induces Immunomodulatory Effect in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Abadier, Michael
    Estevam, Jose
    Berg, Deborah
    Fedyk, Eric Robert
    BLOOD, 2020, 136
  • [25] POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PREVIOUSLY TREATED WITH LENALIDOMIDE
    Gomez, Hernando Marta
    Gironella, Merce
    Abella, Eugenia
    Cabezudo, Elena
    Motllo, Cristina
    Garcia, Antoni
    Sarra, Josep
    Mostacedo, Silvia
    Granell, Miquel
    Rosinol, Laura
    HAEMATOLOGICA, 2020, 105 : 13 - 14
  • [26] Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients
    Badawi, Mohamed Ali
    Engelhardt, Benjamin
    Dobkowska, Edyta
    Deng, Rong
    Kaufman, Jonathan L.
    Menon, Rajeev
    Salem, Ahmed Hamed
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (06) : 635 - 643
  • [27] Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Stiff, Patrick J.
    Ibrahim, Emad
    Vallurupalli, Anusha
    Cull, Elizabeth H.
    Green, Damian J.
    Oliver, Kate
    Longcor, Jarrod
    BLOOD, 2019, 134
  • [28] Treatment patterns among patients with relapsed/refractory multiple myeloma (RRMM) in Taiwan
    Huang, Jeffrey Shang-Yi
    Wang, Ming-Chung
    Yeh, Su-Peng
    Chen, Tsai-Yun
    Teng, Chieh-Lin Jerry
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S188 - S189
  • [29] Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    DerSarkissian, Maral
    Duh, Mei Sheng
    Lafeuille, Marie-Helene
    Posner, George
    Ralston, Stephen
    Zagadailov, Erin
    Ba-Mancini, Abbie
    Rifkin, Robert M.
    BLOOD, 2017, 130
  • [30] CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE
    Oriol, A.
    Steinmetz, T.
    Patel, V
    Kutikova, L.
    Schmidt, N.
    Hennies, N.
    Thiess, A.
    Kostev, K.
    Leleu, X.
    VALUE IN HEALTH, 2019, 22 : S497 - S498
12345